Literature DB >> 14666473

A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism.

Akihiro Fujino1, Yoichiro Moriya, Yasuhide Morikawa, Ken Hoshino, Toshihiko Watanabe, Naoki Shimojima, Masaki Kitajima.   

Abstract

PURPOSE: This study examines cytokine levels of aspirates from cystic lymphangiomas after injection of OK-432 and over the course of several weeks to better understand the process of tumor regression.
METHODS: Fluids aspirated from lymphangioma cysts of 3 patients were collected sequentially before and after OK-432 injection. Mononuclear cells (MNCs) were separated and cultured with or without OK-432. Vascular endothelial growth factor (VEGF), soluble VEGF receptor 1 (sVEGFR1), sVEGFR2, transforming growth factor beta-1 (TGF-beta1), interleukin (IL)-6, IL-8, IL-12+p40, tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) levels in the supernatants of the aspirates and the culture supernatants of MNCs were then measured by ELISA.
RESULTS: The aspirates exhibited a marked elevation in IL-6, IL-8, VEGF, and TGF-beta1 levels for a few weeks after the OK-432 injection. IL-6, IL-8, IL-12+p40, TNF-alpha, and IFN-gamma levels were elevated in the culture supernatants of the MNC cultured with OK-432 for up to 9 days. All the tumors regressed significantly, with sclerotic change, within 3 months after OK-432 injection.
CONCLUSIONS: Cytokine production is maintained for a few weeks after OK-432 injection. Fibrotic changes may be another main mechanism in tumor regression in addition to cytotoxic effects on lymphangioma cells. A close relationship between cytokines from intracystic cells and lymphangioma cells is suggested.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666473     DOI: 10.1016/j.jpedsurg.2003.08.041

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  11 in total

1.  A case of chylothorax treated curatively with Sapylin, a streptococcus preparation.

Authors:  Zhi-hao Xu; Chun-fu Wang; Yue-qin Zhang; Hua-hao Shen; Feng Xu
Journal:  J Zhejiang Univ Sci B       Date:  2007-12       Impact factor: 3.066

2.  Further experience with OK-432 for lymphangiomas.

Authors:  C Luzzatto; R Lo Piccolo; F Fascetti Leon; G F Zanon; T Toffolutti; A Tregnaghi
Journal:  Pediatr Surg Int       Date:  2005-10-25       Impact factor: 1.827

3.  Treatment of lymphatic malformations of head and neck with OK-432 sclerotherapy induce systemic inflammatory response.

Authors:  Mervi Närkiö-Mäkelä; Teppo Mäkelä; Pia Saarinen; Päivi Salminen; Ilkka Julkunen; Anne Pitkäranta
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-16       Impact factor: 2.503

4.  Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results.

Authors:  Eiji Kashiwagi; Yusuke Ono; Hiroki Yano; Shinya Kosai; Keisuke Nagai; Kaishu Tanaka; Hiroki Higashihara; Noriyuki Tomiyama
Journal:  CVIR Endovasc       Date:  2022-10-20

5.  Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation.

Authors:  Tomoyuki Tano; Masato Okamoto; Shin Kan; Takashi Bando; Hiroyuki Goda; Koh-ichi Nakashiro; Shigetaka Shimodaira; Shigeo Koido; Sadamu Homma; Tomonobu Fujita; Mitsunobu Sato; Naomi Yamashita; Hiroyuki Hamakawa; Yutaka Kawakami
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

6.  TLR4 preconditioning is associated with low success of OK-432 treatment for lymphatic malformations in children.

Authors:  Marc Reismann; Nader Ghaffarpour; Ethel Luvall; Adan Jirmo; Josephine Radtke; Gösta Claesson; Tomas Wester
Journal:  Pediatr Surg Int       Date:  2016-01-22       Impact factor: 1.827

7.  Efficacy of OK-432 sclerotherapy in treatment of lymphatic malformations: long-term follow-up results.

Authors:  Annamaria Weitz-Tuoretmaa; Riitta Rautio; Jan Valkila; Harri Keski-Säntti; Leo Keski-Nisula; Jussi Laranne
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-07       Impact factor: 2.503

Review 8.  Recent Progress in Lymphangioma.

Authors:  Xiaowei Liu; Cheng Cheng; Kai Chen; Yeming Wu; Zhixiang Wu
Journal:  Front Pediatr       Date:  2021-12-15       Impact factor: 3.418

9.  Lymphatic malformations of the orbit.

Authors:  Susanne Wiegand; Behfar Eivazi; Linda M Bloch; Annette P Zimmermann; Andreas M Sesterhenn; Stephan Schulze; Jochen A Werner
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-03-08       Impact factor: 3.372

10.  Sclerotherapy for the Management of Seromas: A Systematic Review.

Authors:  Aditya Sood; Vasanth S Kotamarti; Paul J Therattil; Edward S Lee
Journal:  Eplasty       Date:  2017-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.